Print

Print


.

.



MEDICAL: HEART :

HEALTH :

GUIDELINES :

ORGANIZATIONS: AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION

MEDICAL: CARDIOLOGY :

MEDICAL: BLOOD PRESSURE:

2017 Guideline for High Blood Pressure in Adults

.

.


2017 Guideline for High Blood Pressure in Adults

AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION


*Authors:*




*Whelton PK, Carey RM, Aronow WS, et al. *


*Citation:*
*2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the
Prevention, Detection, Evaluation, and Management of High Blood Pressure in
Adults: A Report of the American College of Cardiology/American Heart
Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol
2017;Nov 13:[Epub ahead of print].
<http://www.onlinejacc.org/lookup/doi/10.1016/j.jacc.2017.11.006>*


*http://www.acc.org/latest-in-cardiology/ten-points-to-remember/2017/11/09/11/41/2017-guideline-for-high-blood-pressure-in-adults
<http://www.acc.org/latest-in-cardiology/ten-points-to-remember/2017/11/09/11/41/2017-guideline-for-high-blood-pressure-in-adults>*



*The following are key points to remember from the 2017 Guideline for the
Prevention, Detection, Evaluation, and Management of High Blood Pressure in
Adults:*




*Part 1: General Approach, Screening, and Follow-up*

   1.






*The 2017 guideline is an update of the “Seventh Report of the Joint
   National Committee on Prevention, Detection, Evaluation and Treatment of
   High Blood Pressure” (JNC 7), published in 2003. The 2017 guideline is a
   comprehensive guideline incorporating new information from studies
   regarding blood pressure (BP)-related risk of cardiovascular disease (CVD),
   ambulatory BP monitoring (ABPM), home BP monitoring (HBPM), BP thresholds
   to initiate antihypertensive drug treatment, BP goals of treatment,
   strategies to improve hypertension treatment and control, and various other
   important issues. *
   2.








* It is critical that health care providers follow the standards for
   accurate BP measurement. BP should be categorized as normal, elevated, or
   stages 1 or 2 hypertension to prevent and treat high BP. Normal BP is
   defined as <120/<80 mm Hg; elevated BP 120-129/<80 mm Hg; hypertension
   stage 1 is 130-139 or 80-89 mm Hg, and hypertension stage 2 is ≥140 or ≥90
   mm Hg. Prior to labeling a person with hypertension, it is important to use
   an average based on ≥2 readings obtained on ≥2 occasions to estimate the
   individual’s level of BP. Out-of-office and self-monitoring of BP
   measurements are recommended to confirm the diagnosis of hypertension and
   for titration of BP-lowering medication, in conjunction with clinical
   interventions and telehealth counseling. Corresponding BPs based on
   site/methods are: office/clinic  140/90, HBPM 135/85, daytime ABPM 135/85,
   night-time ABPM 120/70, and 24-hour ABPM 130/80 mm Hg. In adults with an
   untreated systolic BP (SBP) >130 but <160 mm Hg or diastolic BP (DBP) >80
   but <100 mm Hg, it is reasonable to screen for the presence of white coat
   hypertension using either daytime ABPM or HBPM prior to diagnosis of
   hypertension. In adults with elevated office BP (120-129/<80) but not
   meeting the criteria for hypertension, screening for masked hypertension
   with daytime ABPM or HBPM is reasonable. *



   1.

* For an adult 45 years of age without hypertension, the 40-year risk for
   developing hypertension is 93% for African Americans, 92% for Hispanics,
   86% for whites, and 84% for Chinese adults. In 2010, hypertension was the
   leading cause of death and disability-adjusted life-years worldwide, and a
   greater *
   2.
*contributor to events in women and African Americans compared with
   whites.  Often overlooked, the risk for CVD increases in a log-linear
   fashion; *




   1.
*from SBP levels <115 mm Hg to >180 mm Hg, and from DBP levels <75 mm Hg to
   >105 mm Hg. A 20 mm Hg higher SBP and 10 mm Hg higher DBP *



   1.
*are each associated with a doubling in the risk of death from stroke,
   heart disease, or other vascular disease. In persons ≥30 years of age,
   higher SBP *




   1.
*and DBP are associated with increased risk for CVD, angina, myocardial
   infarction (MI), heart failure (HF), stroke, peripheral arterial disease,
   and abdominal *



   1. *aortic aneurysm. SBP has consistently been associated with increased
   CVD risk after adjustment for, or within strata of, SBP; this is not true
   for DBP. *



   1.




* It is important to screen for and manage other CVD risk factors in adults
   with hypertension: smoking, diabetes, dyslipidemia, excessive weight, low
   fitness, unhealthy diet, psychosocial stress, and sleep apnea. Basic
   testing for primary hypertension includes fasting blood glucose, complete
   blood cell count, lipids, basic metabolic panel, thyroid stimulating
   hormone, urinalysis, electrocardiogram with optional echocardiogram, uric
   acid, and urinary albumin-to-creatinine ratio. *
   2.










* Screening for secondary causes of hypertension is necessary for new-onset
   or uncontrolled hypertension in adults including drug-resistant (≥3 drugs),
   abrupt onset, age <30 years, excessive target organ damage (cerebral
   vascular disease, retinopathy, left ventricular hypertrophy, HF with
   preserved ejection fraction [HFpEF] and HF with reserved EF [HFrEF],
   coronary artery disease [CAD], chronic kidney disease [CKD], peripheral
   artery disease, albuminuria) or for onset of diastolic hypertension in
   older adults or in the presence of unprovoked or excessive hypokalemia.
   Screening includes testing for CKD, renovascular disease, primary
   aldosteronism, obstructive sleep apnea, drug-induced hypertension
   (nonsteroidal anti-inflammatory drugs, steroids/androgens, decongestants,
   caffeine, monoamine oxidase inhibitors), and alcohol-induced hypertension.
   If more specific clinical characteristics are present, screening for
   uncommon causes of secondary hypertension is indicated (pheochromocytoma,
   Cushing’s syndrome, congenital adrenal hyperplasia, hypothyroidism,
   hyperthyroidism, and aortic coarctation). Physicians are advised to refer
   patients screening positive for these conditions to a clinician with
   specific expertise in the condition. *
   3.





* Nonpharmacologic interventions to reduce BP include: weight loss for
   overweight or obese patients with a heart healthy diet, sodium restriction,
   and potassium supplementation within the diet; and increased physical
   activity with a structured exercise program. Men should be limited to no
   more than 2 and women no more than 1 standard alcohol drink(s) per day. The
   usual impact of each lifestyle change is a 4-5 mm Hg decrease in SBP and
   2-4 mm Hg decrease in DBP; but diet low in sodium, saturated fat, and total
   fat and increase in fruits, vegetables, and grains may decrease SBP by
   approximately 11 mm Hg. *
   4.










* The benefit of pharmacologic treatment for BP reduction is related to
   atherosclerotic CVD (ASCVD) risk. For a given magnitude reduction of BP,
   fewer individuals with high ASCVD risk would need to be treated to prevent
   a CVD event (i.e., lower number needed to treat) such as in older persons,
   those with coronary disease, diabetes, hyperlipidemia, smokers, and CKD.
   Use of BP-lowering medications is recommended for secondary prevention of
   recurrent CVD events in patients with clinical CVD and an average SBP ≥130
   mm Hg or a DBP ≥80 mm Hg, or for primary prevention in adults with no
   history of CVD but with an estimated 10-year ASCVD risk of  ≥10% and SBP
   ≥130 mm Hg or DBP ≥80 mm Hg. Use of BP-lowering medication is also
   recommended for primary prevention of CVD in adults with no history of CVD
   and with an estimated 10-year ASCVD risk <10% and a SBP ≥140 mm Hg or a DBP
   ≥90 mm Hg. The prevalence of hypertension is lower in women compared with
   men until about the fifth decade, but is higher later in life. While no
   randomized controlled trials have been powered to assess outcome
   specifically in women (e.g., SPRINT), other than special recommendations
   for management of hypertension during pregnancy, there is no evidence that
   the BP threshold for initiating drug treatment, the treatment target, the
   choice of initial antihypertensive medication, or the combination of
   medications for lowering BP differs for women compared with men. For adults
   with confirmed hypertension and known CVD or 10-year ASCVD event risk of
   10% or higher, a BP target of <130/80 mm Hg is recommended. For adults with
   confirmed hypertension, but without additional markers of increased CVD
   risk, a BP target of <130/80 mm Hg is recommended as reasonable.*



*The complete guidelines may be read at the web address above.*

*Related Links and Citations*



Suggested Materials

   - *New ACC/AHA High Blood Pressure Guidelines Lower Definition of
   Hypertension
   <http://www.acc.org/latest-in-cardiology/articles/2017/11/08/11/47/mon-5pm-bp-guideline-aha-2017>*
   - *Guidelines Made Simple | 2017 Guideline for the Prevention,
   Detection, Evaluation, and Management of High Blood Pressure in Adults
   <http://www.acc.org/education-and-meetings/image-and-slide-gallery/media-detail?id=BDA0F36F3160426FAB2E784B82E2629A>*
   - *Slide Set | 2017 Guideline for the Prevention, Detection, Evaluation,
   and Management of High Blood Pressure in Adults
   <http://www.acc.org/education-and-meetings/image-and-slide-gallery/media-detail?id=CF4EBD8CC6F343B98989AB1793ADCF19>*
   - *Full AHA 2017 Coverage
   <http://www.acc.org/latest-in-cardiology/features/meeting-coverage/2017/aha-2017-meeting-coverage>*
   - *Guideline Hub | High Blood Pressure
   <http://www.acc.org/guidelines/hubs/high-blood-pressure>*
   - *JACC High Blood Pressure Guideline Hub
   <http://www.onlinejacc.org/guidelines/highbloodpressure>*

*YOU ARE HERE: Home <http://www.acc.org/> > Latest in Cardiology
<http://www.acc.org/latest-in-cardiology> > 2017 Guideline for High Blood
Pressure in Adults *
Guidelines <http://www.acc.org/guidelines> JACC Journals on ACC.org
<http://www.acc.org/jacc-journals>

   - *JACC <http://www.acc.org/jacc-journals#journal=Journal of the
   American College of Cardiology>*
   - *JACC Interventions <http://www.acc.org/jacc-journals?#journal=JACC:
   Cardiovascular Interventions>*
   - *JACC Imaging <http://www.acc.org/jacc-journals#journal=JACC:
   Cardiovascular Imaging>*
   - *JACC Heart Failure <http://www.acc.org/jacc-journals#journal=JACC:
   Heart Failure>*
   - *JACC Electrophysiology
   <http://www.acc.org/jacc-journals#journal=JACC: Clinical Electrophysiology>*
   - *JACC Basic to Translational Science
   <http://www.acc.org/jacc-journals#journal=JACC: Basic to Translational
   Science/>*

Membership <http://www.acc.org/membership>

   - *About Membership <http://www.acc.org/membership/about-membership>*
   - *Become a Member <http://www.acc.org/membership/become-a-member>*
   - *Renew Your Membership
   <http://www.acc.org/membership/renew-your-membership>*
   - *Member Benefits and Resources
   <http://www.acc.org/membership/member-benefits-and-resources>*
   - *Member Sections <http://www.acc.org/membership/sections-and-councils>*
   - *Chapters <http://www.acc.org/membership/chapters>*
   - *Member Directory <http://www.acc.org/membership/member-directory>*

About ACC <http://www.acc.org/about-acc>

   - *Our Strategic Direction
   <http://www.acc.org/about-acc/our-strategic-direction>*
   - *Our History <http://www.acc.org/about-acc/our-history>*
   - *Our Bylaws and Code of Ethics
   <http://www.acc.org/about-acc/our-bylaws-and-code-of-ethics>*
   - *Leadership and Governance <http://www.acc.org/about-acc/leadership>*
   - *Industry Relations <http://www.acc.org/about-acc/industry-relations>*
   - *Support the ACC <http://www.acc.org/about-acc/support-the-acc>*
   - *Jobs at the ACC <http://www.acc.org/about-acc/jobs-at-the-acc>*
   - *Press Releases <http://www.acc.org/about-acc/press-releases>*
   - *Social Media <http://www.acc.org/about-acc/social-media>*
   - *Book Our Conference Center
   <http://www.acc.org/about-acc/book-our-conference-center>*

Clinical Topics <http://www.acc.org/clinical-topics>

   - *Acute Coronary Syndromes
   <http://www.acc.org/clinical-topics/acute-coronary-syndromes>*
   - *Anticoagulation Management
   <http://www.acc.org/clinical-topics/anticoagulation-management>*
   - *Arrhythmias and Clinical EP
   <http://www.acc.org/clinical-topics/arrhythmias-and-clinical-ep>*
   - *Cardiac Surgery <http://www.acc.org/clinical-topics/cardiac-surgery>*
   - *Cardio-Oncology <http://www.acc.org/clinical-topics/cardio-oncology>*
   - *Chronic Angina <http://www.acc.org/clinical-topics/chronic-angina>*
   -
*Congenital Heart Disease and     Pediatric Cardiology
   <http://www.acc.org/clinical-topics/congenital-heart-disease-pediatric-cardiology>*
   -
*Diabetes and Cardiometabolic     Disease
   <http://www.acc.org/clinical-topics/diabetes-and-cardiometabolic-disease>*
   - *Dyslipidemia <http://www.acc.org/clinical-topics/dyslipidemia>*
   - *Geriatric Cardiology
   <http://www.acc.org/clinical-topics/geriatric-cardiology>*
   - *Heart Failure and Cardiomyopathies
   <http://www.acc.org/clinical-topics/heart-failure-and-cardiomyopathies>*
   -
*Invasive Cardiovascular Angiography    and Intervention
   <http://www.acc.org/clinical-topics/invasive-cardiovascular-angiography-and-intervention>*
   - *Mitral Regurgitation
   <http://www.acc.org/clinical-topics/valvular-heart-disease/mitral-regurgitation>*
   - *Noninvasive Imaging
   <http://www.acc.org/clinical-topics/noninvasive-imaging>*
   - *Pericardial Disease
   <http://www.acc.org/clinical-topics/pericardial-disease>*
   - *Prevention <http://www.acc.org/clinical-topics/prevention>*
   -
*Pulmonary Hypertension and Venous     Thromboembolism
   <http://www.acc.org/clinical-topics/pulmonary-hypertension-and-venous-thromboembolism>*
   - *Sports and Exercise Cardiology
   <http://www.acc.org/clinical-topics/sports-and-exercise-cardiology>*
   - *Stable Ischemic Heart Disease
   <http://www.acc.org/clinical-topics/stable-ischemic-heart-disease>*
   - *Valvular Heart Disease
   <http://www.acc.org/clinical-topics/valvular-heart-disease>*
   - *Vascular Medicine
   <http://www.acc.org/clinical-topics/vascular-medicine>*

Latest in Cardiology <http://www.acc.org/latest-in-cardiology>

   - *Clinical Updates & Discoveries
   <http://www.acc.org/latest-in-cardiology#theme=Clinical Updates and
   Discoveries>*
   - *Advocacy & Policy
   <http://www.acc.org/latest-in-cardiology#theme=Advocacy and Policy>*
   - *Perspectives & Analysis
   <http://www.acc.org/latest-in-cardiology#theme=Perspectives and Analysis>*
   - *Meeting Coverage
   <http://www.acc.org/latest-in-cardiology#theme=Meeting Coverage>*

Education and Meetings <http://www.acc.org/education-and-meetings>

   - *Online Learning Catalog
   <http://www.acc.org/education-and-meetings/education-catalog>*
   - *Understanding MOC
   <http://www.acc.org/education-and-meetings/maintenance-of-certification-information-hub>*
   - *Products and Resources
   <http://www.acc.org/education-and-meetings/products-and-resources>*
   - *Image and Slide Gallery
   <http://www.acc.org/education-and-meetings/image-and-slide-gallery>*
   - *Meetings <http://www.acc.org/education-and-meetings/meetings>*
   - *Annual Scientific Session <https://accscientificsession.acc.org/>*

Tools and Practice Support <http://www.acc.org/tools-and-practice-support>

   - *Quality Improvement for Institutions <http://cvquality.acc.org/>*
   - *NCDR <https://www.ncdr.com/webncdr/>*
   - *CardioSmart <https://www.cardiosmart.org/>*
   - *ACC Accreditation Services <http://accreditation.acc.org>*
   - *Clinical Toolkits
   <http://www.acc.org/tools-and-practice-support/clinical-toolkits>*
   - *Mobile Resources
   <http://www.acc.org/tools-and-practice-support/mobile-resources>*
   - *Advocacy at the ACC
   <http://www.acc.org/tools-and-practice-support/advocacy-at-the-acc>*
   - *Cardiology Careers <http://www.healthecareers.com/acc>*
   - *Practice Solutions
   <http://www.acc.org/tools-and-practice-support/practice-solutions>*
   - *Quality Programs
   <http://www.acc.org/tools-and-practice-support/quality-programs>*


   - *[image: YouTube] <https://www.youtube.com/user/ACCinTouch>*
   - *[image: LinkedIn]
   <http://www.linkedin.com/groups/American-College-Cardiology-732607?trk=myg_ugrp_ovr>*
   - *[image: Facebook]
   <https://www.facebook.com/AmericanCollegeofCardiology>*
   - *[image: Twitter] <https://twitter.com/accintouch>*


   - *JACC <http://www.onlinejacc.org>*
   - *Quality Improvement for Institutions <http://cvquality.acc.org/>*
   - *NCDR <http://cvquality.acc.org/NCDR-Home.aspx>*
   - *CardioSmart <https://www.cardiosmart.org/For-Clinicians>*
   - *ACC Accreditation Services <http://accreditation.acc.org>*

*Heart House**2400 N Street NW**Washington DC, 20037* *Phone:*
*(800) 253-4636 <//1-800-253-4636>, ext. 5603 or* *(202) 375-6000
<//1-202-375-6000>, ext. 5603**E-mail:**[log in to unmask] <[log in to unmask]>*
*Fax:**(202) 375-7000*





*Sincerely,*

*David Dillard*

*Temple University*

*(215) 204 - 4584*

*[log in to unmask] <[log in to unmask]>*

*http://workface.com/e/daviddillard <http://workface.com/e/daviddillard>*


*Net-Gold*

*http://groups.yahoo.com/group/net-gold
<http://groups.yahoo.com/group/net-gold>*





*http://listserv.temple.edu/archives/net-gold.html
<http://listserv.temple.edu/archives/net-gold.html>https://groups.io/org/groupsio/Net-Gold/archives
<https://groups.io/org/groupsio/Net-Gold/archives>http://net-gold.3172864.n2.nabble.com/
<http://net-gold.3172864.n2.nabble.com/>*

*General Internet & Print Resources*

*http://tinyurl.com/pwyg37u <http://tinyurl.com/pwyg37u>*

*COUNTRIES*

*http://tinyurl.com/p7s2z4u <http://tinyurl.com/p7s2z4u>*

*EMPLOYMENT*

*http://tinyurl.com/oxa9w52 <http://tinyurl.com/oxa9w52>*

*TOURISM*

*http://tinyurl.com/pnla2o9 <http://tinyurl.com/pnla2o9>*

*DISABILITIES*

*http://tinyurl.com/pl7gorq <http://tinyurl.com/pl7gorq>*



*INDOOR
GARDENINGhttps://groups.yahoo.com/neo/groups/IndoorGardeningUrban/info
<https://groups.yahoo.com/neo/groups/IndoorGardeningUrban/info>*

*Educator-Gold*

*http://groups.yahoo.com/group/Educator-Gold/
<http://groups.yahoo.com/group/Educator-Gold/>*

*K12ADMINLIFE*

*http://groups.yahoo.com/group/K12AdminLIFE/
<http://groups.yahoo.com/group/K12AdminLIFE/>*

*The Russell Conwell Learning Center Research Guide:*

*THE COLLEGE LEARNING CENTER*

*http://tinyurl.com/obcj6rf <http://tinyurl.com/obcj6rf>*

*Information Literacy*

*http://tinyurl.com/78a4shn <http://tinyurl.com/78a4shn>*


*Research Guides*

*https://sites.google.com/site/researchguidesonsites/
<https://sites.google.com/site/researchguidesonsites/>*


*Twitter: davidpdillard*


*Temple University Site Map*

*https://sites.google.com/site/templeunivsitemap/home
<https://sites.google.com/site/templeunivsitemap/home>*


*Bushell, R. & Sheldon, P. (eds),*

*Wellness and Tourism: Mind, Body, Spirit,*

*Place, New York: Cognizant Communication Books.*

*Wellness Tourism: Bibliographic and Webliographic Essay*

*David P. Dillard*

*http://tinyurl.com/p63whl <http://tinyurl.com/p63whl>*


*RailTram Discussion Group*

*From the Union Pacific to BritRail and Beyond*

*https://groups.yahoo.com/neo/groups/railtram/info
<https://groups.yahoo.com/neo/groups/railtram/info>  *


*INDOOR GARDENING*



*Improve Your Chances for Indoor Gardening
Successhttps://groups.yahoo.com/neo/groups/IndoorGardeningUrban/info
<https://groups.yahoo.com/neo/groups/IndoorGardeningUrban/info>*


*SPORT-MED*

*https://www.jiscmail.ac.uk/lists/sport-med.html
<https://www.jiscmail.ac.uk/lists/sport-med.html>*

*http://groups.yahoo.com/group/sports-med/
<http://groups.yahoo.com/group/sports-med/>*

*http://listserv.temple.edu/archives/sport-med.html
<http://listserv.temple.edu/archives/sport-med.html>*




*HEALTH DIET FITNESS RECREATION SPORTS
TOURISMhttps://groups.yahoo.com/neo/groups/healthrecsport/info
<https://groups.yahoo.com/neo/groups/healthrecsport/info>*

*http://listserv.temple.edu/archives/health-recreation-sports-tourism.html
<http://listserv.temple.edu/archives/health-recreation-sports-tourism.html>*